...A. 5 commercial programs globally commercializing with revenue growth still growing in the 20% to 30% range for these programs. B. 9 out of 11 total, we are highly efficient at picking, developing successfully therapeutics. C. We'll have 5 approvals by 10 years. D. And with the slate of products in front of us today, we expect to have something like 8 to 12 approvals during the first 15 years post IPO. E. Key catalysts -- today, we're going to talk about 3, I just mentioned, 143, GTX-102 and UX701, OI, Angelman Wilson disease. F. When we look at our revenue growth over time, we are -- we, of course, have 5 program generating revenue. G. We expect to be adding additional programs. H. We have on deck multiple approvals coming, projecting us to more than $1 billion in revenue in not too long and a path to profitability as a company. I. They then revert into osteocytes, which makes up 90% of bone. J. So we enrolled 24 patients with Type 1, 3 and 4 osteogenesis imperfecta. K. These were patients...
